Editorial Anti-VEGF Therapy: Proactive or Reactive?

Authors

  • Sajjad Mahmood

DOI:

https://doi.org/10.36351/pjo.v32i1.126

Abstract

One of the greatest breakthroughs in ophthalmology occurred only ten years ago following the first publication of the use of intravitreal bevacizumab to treat choroidal

neovascularisation.1 Since then the use of anti-VEGF agents bevacizumab, ranibizumab and aflibercept has spread on a massive scale throughout the world and patients are benefiting from sight-saving therapy for diseases which previously had limited or no effective therapy.

Downloads

Published

17-07-2018

How to Cite

1.
Mahmood S. Editorial Anti-VEGF Therapy: Proactive or Reactive?. pak J Ophthalmol [Internet]. 2018 Jul. 17 [cited 2025 Jan. 4];32(1). Available from: https://pjo.org.pk/index.php/pjo/article/view/126

Issue

Vol. 32 No. 1 (2016): PJO

Section

Review Articles